Anti-CGRP receptor antibodies do not modulate trigeminal pain processing: indication for distinct mechanisms of CGRP pathway blockade
Abstract Background Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptides (CGRP) are established therapies for migraine. There are currently four CGRP-mAbs available on the market: one targets the CGRP receptor, and the other three target the CGRP ligand. Despite the initial compar...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2026-03-01
|
| Serija: | The Journal of Headache and Pain |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s10194-026-02316-z |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|